Literature DB >> 6602181

Generation of low m.w., C3-bearing immunoglobulin in human serum.

R J Jacobs, M Reichlin.   

Abstract

The generation of low m.w. C3-bearing immunoglobulin (lg) in normal human serum by an immune complex (IC) model was investigated in vitro by using discontinuous sucrose density gradient centrifugation (DGC) and an assay that measures C3-bearing Ig. In this method developed to measure circulating IC, all C3 and C3-bearing material is precipitated from serum by using anti-C3 sera in C3d antibody excess, and immune precipitated, C3-bearing Ig is quantitated by the uptake of 125I-5S-anti-IgG. When plasma from patients with clinically active systemic lupus erythematosus was assayed after DGC, most of the reactive material was low m.w. (7S), rather than greater than or equal to 19S as expected for IC, in agreement with a previous report. Low m.w., C3-bearing Ig was found in normal EDTA plasma after extended storage at -29 degrees C but not after storage at -70 degrees C. Such material was also generated in normal human serum during incubation at 37 degrees C and its generation was stimulated by the addition of an IC model, high m.w., heat-aggregated IgG (HMW-HAIgG). In experiments in which the participation of serum IgG was monitored by the addition of 125I-7S-IgG and 131I-HMW-HAIgG was used as an IC model, low m.w., C3-bearing Ig was generated exclusively from serum IgG and the amount generated was proportional to the concentration of 131I-HMW-HAIgG. No significant decrease in sedimentation of 131I-HMW-HAIgG was observed, but the ability of anti-C3 sera to precipitate 131I-HMW-HAIgG decreased 66% 4 hr after initial C activation. These results indicate that generation of nascent C3b in serum results in its interaction with monomeric serum IgG, producing low m.w., C3-bearing IgG. In addition, the data indicate that circulating IC that activate C have a brief time span during which they can be detected by methods that depend upon the binding of C3.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602181

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Authors:  Hans U Lutz; Peter J Späth
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes.

Authors:  A Malbran; M M Frank; L F Fries
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

3.  Complement-component-C3-opsonized immunoglobulin G anti-DNA antibodies do not bind effectively to red blood cells unless aggregated on a high-Mr DNA matrix.

Authors:  C Horgan; R P Taylor
Journal:  Biochem J       Date:  1984-12-15       Impact factor: 3.857

4.  Formation of C3-IgG complexes in serum by aggregated IgG and by non-immunoglobulin activators of complement.

Authors:  A P van Dam; C E Hack
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

5.  Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.

Authors:  M T Aguado; J D Lambris; G C Tsokos; R Burger; D Bitter-Suermann; J D Tamerius; F J Dixon; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

6.  Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.

Authors:  M Basta; P Kirshbom; M M Frank; L F Fries
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

7.  C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I.

Authors:  L F Fries; T A Gaither; C H Hammer; M M Frank
Journal:  J Exp Med       Date:  1984-12-01       Impact factor: 14.307

8.  IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111.

Authors:  K A Joiner; L F Fries; M A Schmetz; M M Frank
Journal:  J Exp Med       Date:  1985-09-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.